DOTATATE PET/MR成像可区分继发性进展性与新发世界卫生组织3级脑膜瘤
前瞻性观察性队列纳入14例世界卫生组织3级脑膜瘤患者,按继发性进展性与新发分层,比较68Ga-DOTATATE PET/MR标准摄取值、分子谱及临床结局。继发性进展性肿瘤手术次数更多、无进展生存期更短、突变数更多、PET标准摄取值更高,提示PET/MR有助于鉴别两类肿瘤。
要点
- 继发性进展性3级脑膜瘤PET标准摄取值高于新发肿瘤(17.1 vs 12.4,P=0.0021)。
- 继发性进展性肿瘤无进展生存期显著短于新发肿瘤(4.8 vs 37.7个月,P=0.004)。
- 继发性进展性肿瘤突变数多于新发肿瘤(3.5 vs 1.2,P=0.024)。
核心结论
- 研究证实继发性进展性与新发世界卫生组织3级脑膜瘤具有不同的临床结局,68Ga-DOTATATE PET/MR成像可能是有用的管理策略。
研究设计与样本
- 前瞻性观察性队列研究,纳入14例世界卫生组织3级脑膜瘤患者(继发性进展性7/14,新发7/14),评估68Ga-DOTATATE PET/MR在生长抑素受体阳性脑肿瘤中的应用。
关键影像表现/征象
- 继发性进展性肿瘤的PET标准摄取值高于新发肿瘤(17.1 vs 12.4,P=0.0021)。
诊断标准与关键数值
- 继发性进展性队列每例患者手术次数显著高于新发队列(4.1 vs 1.6,P=0.011)。
- 继发性进展性队列每例患者放疗疗程数有高于新发队列的趋势(2.4 vs 1.6,P=0.23)。
- 继发性进展性队列累积放疗剂量有高于新发队列的趋势(106Gy vs 68.3Gy,P=0.31)。
- 继发性进展性队列无进展生存期显著短于新发队列(4.8 vs 37.7个月,P=0.004)。
- 继发性进展性肿瘤突变数显著多于新发肿瘤(3.5 vs 1.2,P=0.024)。
临床应用与阅片要点
- 68Ga-DOTATATE PET/MR成像可能有助于区分继发性进展性与新发世界卫生组织3级脑膜瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: WHO grade 3 meningiomas are rare and poorly understood and have a higher propensity for recurrence, metastasis, and worsened clinical outcomes compared with lower-grade meningiomas. The purpose of our study was to prospectively evaluate the molecular profile, PET characteristics, and outcomes of patients with World Health Organization grade 3 meningiomas who were imaged with gallium 68 (68Ga) DOTATATE PET/MR imaging.
MATERIALS AND METHODS: Patients with World Health Organization grade 3 meningiomas enrolled in our prospective observational cohort evaluating the utility of (68Ga) DOTATATE PET/MR imaging in somatostatin receptor positive brain tumors were included. We stratified patients by de novo-versus-secondary-progressive status and evaluated the differences in the PET standard uptake value, molecular profiles, and clinical outcomes.
RESULTS: Patients met the inclusion criteria (secondary-progressive: 7/14; de novo: 7/14). The secondary-progressive cohort had a significantly higher per-patient number of surgeries (4.1 versus 1.6; P = .011) and trended toward a higher number of radiation therapy courses (2.4 versus 1.6; P = .23) and cumulative radiation therapy doses (106Gy versus 68.3Gy; P = .31). The secondary-progressive cohort had a significantly lower progression-free survival compared with the de novo cohort (4.8 versus 37.7 months; P = .004). Secondary-progressive tumors had distinct molecular pathology profiles with higher numbers of mutations (3.5 versus 1.2; P = .024). Secondary-progressive tumors demonstrated higher PET standard uptake values (17.1 versus 12.4; P = .0021).
CONCLUSIONS: Our study confirms prior work illustrating distinct clinical outcomes in secondary-progressive and de novo World Health Organization grade 3 meningiomas. Furthermore, our findings support (68Ga) DOTATATE PET/MR imaging as a useful management strategy in World Health Organization grade 3 meningiomas and provide insight into meningioma biology, as well as clinical management implications.
引用
- Kim JT, Chang SJC, Haghdel A, et al. DOTATATE PET/MR Imaging Differentiates Secondary-Progressive from de Novo World Health Organization Grade 3 Meningiomas. AJNR Am J Neuroradiol. 2024. PMID: 38604734. doi:10.3174/ajnr.A8219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。